← Back to headlines
Piper Sandler Sees Path to Growth for Bristol-Myers Squibb Company (BMY) After Eliquis Patent Expiry
Piper Sandler analysts foresee a path to growth for Bristol-Myers Squibb Company (BMY) following the expiry of its Eliquis patent, suggesting new opportunities for the pharmaceutical firm.
12 Mar, 06:36 — 12 Mar, 06:36
Sources
Showing 1 of 1 sources
